Barclays’s HilleVax HLVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-449
| Closed | -$894 | – | 5592 |
|
|
2025
Q2 | $894 | Sell |
449
-31,670
| -99% | -$57.9K | ﹤0.01% | 5064 |
|
|
2025
Q1 | $46.6K | Sell |
32,119
-15,827
| -33% | -$29.3K | ﹤0.01% | 4628 |
|
|
2024
Q4 | $99.2K | Buy |
47,946
+5,913
| +14% | +$11.1K | ﹤0.01% | 4595 |
|
|
2024
Q3 | $74K | Buy |
42,033
+30,213
| +256% | +$77.5K | ﹤0.01% | 4644 |
|
|
2024
Q2 | $171K | Sell |
11,820
-60,450
| -84% | -$831K | ﹤0.01% | 3658 |
|
|
2024
Q1 | $1.2M | Buy |
72,270
+32,362
| +81% | +$518K | ﹤0.01% | 2972 |
|
|
2023
Q4 | $641K | Buy |
39,908
+33,534
| +526% | +$446K | ﹤0.01% | 3724 |
|
|
2023
Q3 | $85.7K | Buy |
6,374
+375
| +6% | +$5.28K | ﹤0.01% | 3652 |
|
|
2023
Q2 | $103K | Sell |
5,999
-2,869
| -32% | -$44.5K | ﹤0.01% | 3546 |
|
|
2023
Q1 | $147K | Buy |
8,868
+4,180
| +89% | +$66.9K | ﹤0.01% | 3973 |
|
|
2022
Q4 | $78.4K | Buy |
4,688
+4,139
| +754% | +$74.7K | ﹤0.01% | 4368 |
|
|
2022
Q3 | $9K | Sell |
549
-101
| -16% | -$1.47K | ﹤0.01% | 4357 |
|
|
2022
Q2 | $7K | Buy |
+650
| New | +$7.72K | ﹤0.01% | 4718 |
|
Barclays's HLVX Position: Q3 2025 in Review
Barclays sold out of HilleVax (HLVX) in Q3 2025, closing a stake of 449 shares — an estimated $894 sold.
Barclays first reported a position in HLVX in Q2 2022 and held it in 13 quarters. The position peaked at $1.2M in Q1 2024. 1 fund tracked by Wall St. Rank holds HLVX as of Q3 2025.
- Barclays reported no remaining HilleVax position as of Q3 2025 after selling out during the quarter.
- Barclays sold 449 HilleVax shares in Q3 2025, an estimated $894.
- Barclays first reported a position in HilleVax in Q2 2022 and held it in 13 quarters.
- Barclays's HilleVax position peaked at $1.2M in Q1 2024.
- 1 fund tracked by Wall St. Rank held HilleVax as of Q3 2025.
Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.